Wednesday, Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2023 revenues of $291 million, down from $357 million a year ago, missing the consensus of $321.97 million. Total revenue for 2023 was $984 million, compared to $2 billion in the same period in 2022.
Net loss for the fourth quarter of 2023 was $178 million, compared to a net loss of $182 million a year ago.
Novavax’s fourth quarter EPS loss reached $(1.44), up from $(2.28) a year ago compared to the consensus of $(0.45).
The company expects to initiate a pivotal Phase 3 trial for the COVID-19-Influenza Combination (CIC) vaccine candidate in the second …